Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) - Zacks Research raised their Q1 2025 EPS estimates for Gilead Sciences in a report released on Monday, November 4th. Zacks Research analyst E. Bagri now forecasts that the biopharmaceutical company will post earnings of $1.63 per share for the quarter, up from their previous forecast of $1.62. The consensus estimate for Gilead Sciences' current full-year earnings is $3.75 per share. Zacks Research also issued estimates for Gilead Sciences' Q3 2025 earnings at $2.04 EPS, Q4 2025 earnings at $1.80 EPS, Q1 2026 earnings at $1.62 EPS and Q3 2026 earnings at $2.11 EPS.
Gilead Sciences (NASDAQ:GILD - Get Free Report) last issued its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported $2.01 EPS for the quarter, topping analysts' consensus estimates of $1.61 by $0.40. The firm had revenue of $6.95 billion during the quarter, compared to analyst estimates of $6.64 billion. Gilead Sciences had a return on equity of 29.34% and a net margin of 3.79%.
A number of other equities analysts also recently issued reports on GILD. Piper Sandler reiterated an "overweight" rating and issued a $95.00 target price on shares of Gilead Sciences in a research note on Wednesday, September 11th. JPMorgan Chase & Co. increased their price objective on shares of Gilead Sciences from $95.00 to $100.00 and gave the company an "overweight" rating in a research note on Wednesday, October 9th. Royal Bank of Canada restated a "sector perform" rating and issued a $75.00 target price on shares of Gilead Sciences in a research note on Tuesday, October 29th. Wells Fargo & Company raised Gilead Sciences from an "equal weight" rating to an "overweight" rating and increased their price target for the company from $78.00 to $100.00 in a research report on Monday, October 7th. Finally, Leerink Partnrs raised Gilead Sciences from a "hold" rating to a "strong-buy" rating in a research report on Monday, October 21st. Ten investment analysts have rated the stock with a hold rating, eleven have given a buy rating and three have issued a strong buy rating to the company's stock. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $86.85.
Check Out Our Latest Analysis on GILD
Shares of Gilead Sciences stock opened at $90.22 on Wednesday. The company has a market capitalization of $112.32 billion, a P/E ratio of 110.02, a price-to-earnings-growth ratio of 3.12 and a beta of 0.17. The stock has a fifty day simple moving average of $84.32 and a 200 day simple moving average of $74.55. Gilead Sciences has a 12-month low of $62.07 and a 12-month high of $90.71. The company has a current ratio of 1.14, a quick ratio of 0.95 and a debt-to-equity ratio of 1.18.
A number of hedge funds and other institutional investors have recently bought and sold shares of GILD. Vanguard Group Inc. grew its position in shares of Gilead Sciences by 2.6% during the 1st quarter. Vanguard Group Inc. now owns 114,732,575 shares of the biopharmaceutical company's stock valued at $8,404,161,000 after purchasing an additional 2,910,147 shares in the last quarter. Swedbank AB bought a new stake in Gilead Sciences during the first quarter valued at $134,489,000. International Assets Investment Management LLC grew its position in Gilead Sciences by 8,238.4% during the third quarter. International Assets Investment Management LLC now owns 1,642,504 shares of the biopharmaceutical company's stock worth $137,708,000 after buying an additional 1,622,806 shares in the last quarter. Capital Research Global Investors increased its stake in Gilead Sciences by 2.7% in the 1st quarter. Capital Research Global Investors now owns 61,246,366 shares of the biopharmaceutical company's stock worth $4,486,296,000 after acquiring an additional 1,589,240 shares during the last quarter. Finally, Pacer Advisors Inc. raised its holdings in shares of Gilead Sciences by 24.7% in the 2nd quarter. Pacer Advisors Inc. now owns 7,889,663 shares of the biopharmaceutical company's stock valued at $541,310,000 after acquiring an additional 1,564,792 shares in the last quarter. Institutional investors own 83.67% of the company's stock.
In related news, insider Merdad Parsey sold 2,000 shares of the company's stock in a transaction that occurred on Tuesday, October 1st. The shares were sold at an average price of $83.83, for a total transaction of $167,660.00. Following the sale, the insider now directly owns 100,189 shares in the company, valued at approximately $8,398,843.87. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. In related news, insider Merdad Parsey sold 2,000 shares of the business's stock in a transaction on Tuesday, October 1st. The stock was sold at an average price of $83.83, for a total transaction of $167,660.00. Following the sale, the insider now directly owns 100,189 shares in the company, valued at approximately $8,398,843.87. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Johanna Mercier sold 5,490 shares of the firm's stock in a transaction dated Tuesday, August 13th. The stock was sold at an average price of $73.98, for a total value of $406,150.20. Following the completion of the transaction, the insider now owns 114,979 shares of the company's stock, valued at approximately $8,506,146.42. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 36,847 shares of company stock worth $3,033,340 over the last quarter. Corporate insiders own 0.29% of the company's stock.
Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Gilead Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Gilead Sciences wasn't on the list.
While Gilead Sciences currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.